Biotech Values

[DewDiligence]

For the first time the analyst who provided the script numbers commented that TEVA has a generic near approval that will take the majority of the generic market.

This analyst is evidently clueless insofar as Teva has not even submitted its response to the FDA’s questions (see transcript in #msg-59688528); until then, approval is an impossibility.

Please don’t tell the analyst that he/she is clueless, however; I would like to continue to get the weekly script numbers :- )